Early administration of inhaled tobramycin in patients with severe multiple trauma

The aim of this study was to investigate efficacy and safety of early supplemental administration of inhaled tobramycin for prevention and treatment of hospital-acquired pneumonia (HAP) in patients with severe multiple trauma. Methods. Fifty four patients with severe multiple trauma were divided into 2 groups: the study group (n = 27) who took inhaled tobramycin added to systemic antibiotics and the control group (n = 27) who took standard systemic antibacterial treatment. Baselines characteristics did not differ between the groups. The patients' status was assessed daily using APACHE II and CPIS scales. Results. Frequency of HP in the study group was as twice as rare compared to the controls with correspondent reduction in days in ICU. The groups did not differ in mechanical ventilation parameters and frequency of sepsis. CPIS and APACHE II scores did not increase in the inhaled tobramycin group whereas CPIS total score increased and APACHE II score did not improve in the control group. To the 5^th day, significant between-group difference was found in CPIS (p = 0.0028) and APACHE-II (р = 0.0004). Conclusion. Early administration of inhaled tobramycin 600 mg daily added to the standard systemic antibacterial therapy is safe and effective in prevention and treatment of HAP in patients with severe multiple trauma. Such therapy decreased frequency of pulmonary infectious complications and significantly reduced duration of treatment in ICU.

1. ​Keel M., Trentz O. Pathophysiology of polytrauma. Injury. 2005; 36 (6): 691–709.

2. ​Stahel P.F., Heyde C.E., Wyrwich W., Ertel W. Current concepts of polytrauma management: from ATLS to "damage control". Orthopade. 2005; 34 (9): 823–836.

3. ​Ermolov A.S., Abakumov M.M., Sokolov V.A. et al. In-hospital mortality in multiple trauma and ways of its reduction. Khirurgiya. 2006; 9: 17–20 (in Russian).

4. ​Kollef M.H. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit. Care Med. 2004; 32 (6): 1396–1405.

5. ​Khubutiya M.Sh., Shabanov A.K, Chernen'kaya T.V. et al. Infectious pulmonary complications in ICU in patients with multiple trauma. Obshchaya reanimatologiya. 2011; 7 (4): 21–27 (in Russian).

6. ​Karpun N.A., Moroz V.V., Klimova G.M. et al. Prevention of nosocomial respiratory infections. Obshchaya reanimatologiya. 2007; III (3): 100–104 (in Russian).

7. ​Torres A., Rello J. Update in community-acquired and nosocomial pneumonia 2009. Am. J. Respir. Crit. Care Med. 2010; 181 (8): 782–787.

8. ​H#øiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011; 9: 32.

9. ​Golubev A.M., Smelaya T.V., Moroz V.V. et al. Community-acquired pneumonia and hospital-acquired pneumonia: clinical and pathological features. Obshchaya reanimatologiya. 2010; VI (3): 5–14 (in Russian).

10. ​Luna C.M., Vujacich P., Niederman M.S. et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997; 111 (3): 676–685.

11. ​Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998; 113 (2): 412–420.

12. ​Iregui M., Ward S., Sherman G. et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002; 122 (1): 262–268.

13. ​Moroz V.V., Marchenkov Yu.V., Lysenko D.V. et al. Antibacterial treatment of hospital pneumonia caused by multi-drug resistant pathogens in critically ill patients. Obshchaya reanimatologiya. 2007; III (3): 90–94 (in Russian).

14. ​Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir. Care. 2007; 52 (7): 866–884.

15. ​Chermenskiy A.G., Gembitskaya T.E. Inhalation tobramycin in cystic fibrosis patients. Terapevticheskiy arkhiv. 2010; 8: 76–78 (in Russian).

16. ​Kapranov N.I., Kashirskaya N.Yu., Rodionovich A.M. et al. Clinical significance of a special aerosol formulation of tobramycin for therapy of chronic pulmonary disease in cystic fibrosis patients. Pul'monologiya. 2008; 3: 20–27 (in Russian).

17. ​Kapranov N.I., Kashirskaya N.Yu., Nikonova V.S. An experience of outpatient administration of inhaled antibiotics in cystic fibrosis patients with Pseudomonas aeruginosa infection. Lechebnoe delo. 2010; 3: 35–40 (in Russian).

18. ​Amelina E.L., Chuchalin A.G. Inhaled tobramycin in treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Pul'monologiya. 2009; 5: 120–126 (in Russian).

19. ​Belousov Yu.B., Zyryanov S.K., Sokolov A.V. Efficacy and safety of inhaled tobramycin solution for therapy of Pseudomonas aeruginosa infection in cystic fibrosis. Pul'monologiya. 2010; 2: 114–119 (in Russian).

20. ​Michalopoulos A., Fotakis D., Virtzili S. et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med. 2008; 102 (3): 407–412.

21. ​Michalopoulos A., Papadakis E. Inhaled anti-infective agents: emphasis on colistin. Infection. 2010; 38 (2): 81–88.

22. ​Palmer L.B., Smaldone G.C., Chen J.J. et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit. Care Med. 2008; 36 (7): 2008–2013.

23. ​Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2009; 28 (3): 253–259.

24. ​Hallal A., Cohn S.M., Namias N. et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg. Infect. (Larchmt.). 2007; 8 (1): 73–82.

25. ​Avdeev S.N., Karchevskaya N.A., Chuchalin A.G. An experience of administration of inhaled tobramycin in nosocomial pneumonia. Lechebnoe delo. 2009; 2: 80–88 (in Russian).

26. ​Polovnikov S.G., Kuzovlev A.N., Il'ichev A.N. An experience of administration of inhaled tobramycin in treatment of severe nosocomial pneumonia. Pul'monologiya. 2011; 2: 109–112 (in Russian).

27. ​Levy M.M., Fink M.P., Marshal J.C. et al. 2001 SCCM / ESICM / ACCP / ATS / SIS International Sepsis Definitions Conference. Crit. Care Med. 2003; 31 (4): 1250–1256.

28. ​Chuchalin A.G., Gel'fand B.R., eds. Nosocomial pneumonia in adults. Russian national guidelines. Moscow; 2009 (in Russian).

29. ​Pugin J., Auckenthaler R., Mili N. et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and bronbronchoscopic "blind" bronchoalveolar lavage fluid. Am. Rev. Respir. Dis. 1991; 143 (5, Pt 1): 1121–1129.

30. ​Isenberg H.D., ed. Clinical Microbiology. Procedures Handbook. American Society Microbiology; 2004.

31. ​Afifi A., Eyzen S. Statistical analysis using ECM. Translated from English. Moscow: Mir; 1982: 488 (in Russian).

32. ​Petrie A., Sabin K. Medical statistics at a glance. Translated from English. Moscow: GEOTAR-Media; 2003 (in Russian).

33. ​Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002; 122 (1): 219–226.